Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-007859
Filing Date
2025-04-30
Accepted
2025-04-30 17:00:31
Documents
18
Period of Report
2025-04-30

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT formdef14a.htm   iXBRL DEF 14A 440644
2 GRAPHIC proxy_001.jpg GRAPHIC 1033639
3 GRAPHIC proxy_002.jpg GRAPHIC 392785
  Complete submission text file 0001641172-25-007859.txt   3949760

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE thar-20241231.xsd EX-101.SCH 3423
5 XBRL DEFINITION FILE thar-20241231_def.xml EX-101.DEF 5348
6 XBRL LABEL FILE thar-20241231_lab.xml EX-101.LAB 52577
7 XBRL PRESENTATION FILE thar-20241231_pre.xml EX-101.PRE 39416
21 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 4851
Mailing Address 245 MAIN STREET SUITE 204 CHESTER NJ 07930
Business Address 1200 ROUTE 22 EAST BRIDGEWATER NJ 08807 302-743-2995
Tharimmune, Inc. (Filer) CIK: 0001861657 (see all company filings)

EIN.: 842642541 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41210 | Film No.: 25896620
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)